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Abstract Essential thrombocythaemia (ET) is an acquired
myeloproliferative disorder with a prolonged clinical course
and a near-normal life expectancy. Therapy is stratified
according to risk of thrombohaemorrhagic events. In high-
risk patients, platelet reduction is generally recommended.
In intermediate-risk patients, therapy should be considered
depending on the severity of associated risk factors,
especially cardiovascular. In low-risk patients, a watch-
and-wait approach is appropriate. Hydroxycarbamide is
generally first-line therapy. Concerns for possible leukemo-
genicity make anagrelide or interferon-α possible choices
in younger patients and those who are resistant or intolerant
to hydroxycarbamide. Each pharmacotherapy is associated
with specific long-term risks and benefits. The potential
risk of major bleeding is the main drawback of aspirin.
Hydroxycarbamide is an established, effective drug for ET,
but it may increase the risk of transformation to acute
myeloid leukaemia and may give mucocutaneous ulcers.
Anagrelide is a licensed treatment that also reduces platelet
counts and is generally well tolerated, with evidence that
some common side effects diminish over time. Anagrelide
can have cardiac effects due to inhibition of phosphodies-
terase III and therefore requires cautious use in patients
with cardiac insufficiency. There is no evidence of
leukaemogenicity with anagrelide or interferon-α therapy.
Interferon-α is the only treatment suitable for use during
pregnancy, although it is not licensed in ET. While it is
effective for platelet reduction, the use of interferon-α is
restricted by psychiatric side effects. Our knowledge of the
optimum pharmacotherapy for each patient with ET
continues to evolve through research and clinical trials,
particularly into the molecular basis of the disease.
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Introduction
Essential thrombocythaemia (ET) is an acquired myelopro-
liferative disorder (MPD), characterised by persistent
peripheral thrombocytosis and a tendency for thrombosis
and haemorrhage [1]. For example, in a study of 93 patients
with ET, at a median follow-up of 70 months, 16% of
patients developed thrombosis, 14% developed haemor-
rhage and 17% developed microvascular complications [2].
ET can proceed in some cases to myelofibrosis, acute
myeloid leukaemia (AML), myelodysplastic syndromes
(MDS) or polycythaemia vera (PV) [3]. The estimated
annual incidence of ET based on World Health Organiza-
tion (WHO) criteria is 1–2.5/100,000 individuals [4].
However, the true incidence is likely to be higher as many
patients are without symptoms, and thus undiagnosed. Even
though ET is a rare disease, the prevalence is high at 30/
100,000 general population [1], reflecting the near-normal
life expectancy of patients with the condition [5].
Several lines of evidence suggest that ET is a heteroge-
neous disease entity, though the existence of distinct
subgroups is difficult to validate. Molecular evidence
includes the patient’s JAK2 mutation status (i.e. the
presence or absence of the Janus kinase 2 mutation
JAK2V617F) [3], variation in X-chromosome inactivation
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patterns in females [6] and differences in PV rubra vera-1
(PRV1) mRNA expression (discriminating two types of ET)
[7], while immunohistochemical evidence includes hetero-
geneous c-mpl expression [8]. Differences have also been
observed between patients with ET in the growth of
erythropoietin-independent colonies (EEC). In a study of
molecular markers, growth of EEC was observed in 50–
69% of ET patients [7, 9]. Furthermore, as a group, ET
patients with the JAK2V617F mutation and/or low serum
erythropoietin levels seem to have a more PV-like pheno-
type with slightly higher white blood cell counts and
haemoglobin levels [3, 10, 11].
Diagnosis
The diagnosis of ET includes detection of specific changes
in bone marrow morphology, as well as exclusion of
secondary thrombocytosis caused by other conditions
[12]. Recently, an advisory group to the WHO proposed
revised diagnostic criteria for ET (Table 1) [12]. Using
these criteria, diagnosis is supported by demonstration of a
clonal marker of the condition (e.g. JAK2V617F, present in
approximately 50% of ET patients) [3]; however, identifi-
cation of this mutation cannot differentiate between ET and
other MPDs. Several investigators suggest that some ET
patients diagnosed according to the guidelines of the
Polycythaemia Vera Study Group actually have an early
stage chronic primary myelofibrosis (PMF-0 or ‘false ET’)
[13, 14]. This prefibrotic condition is known to progress to
overt myelofibrosis in a high proportion of patients, thus
differing from ‘true ET’ which does not [15–17]. If this
distinction is valid, it is an important consideration when
evaluating treatment strategies. However, the feasibility of
distinguishing ET from PMF-0 is not generally accepted
among pathologists in clinical practice [18].
The ideal therapeutic agent?
A number of pharmacotherapies have been investigated for
use in ET. The ideal therapeutic treatment should rapidly
lower platelet counts to normal levels, reduce ET-related
complications and symptoms, have limited side effects and
no long-term safety concerns. Long-term benefits and risks
of pharmacotherapy are of particular relevance to patients
with ET, who require prolonged treatment over a lifetime.
This article considers the long-term effects of several ET
treatment options, focusing on the anti-platelet agent,
aspirin, and three cytoreductive therapies: hydroxycarba-
mide, anagrelide and interferon-α. Taking these findings
into consideration, a risk-based treatment algorithm for ET
is proposed.
Literature search
This article contains information from a number of sources,
including relevant searches of PubMed (conducted on 14
November 2007), the author’s own reference database and
the reference lists of recent review articles. It is not
intended as a systematic review.
Acetylsalicyclic acid (aspirin)
Since it was first synthesised in 1897, the use of aspirin has
extended from analgesia to encompass prevention of
cardiovascular events such as myocardial infarction and
ischaemic stroke [19]. Theoretically, aspirin also has a place
in the management of ET, particularly as it has been shown
to suppress excess thromboxane synthesis [20], evident in
patients with ET and PV [20, 21]. Several studies have
confirmed this theory, showing that aspirin reduces throm-
botic complications associated with ET [22, 23] as well as
microvascular events (e.g. neurological symptoms and
erythromelalgia) [24, 25].
The only randomised controlled trial investigating use of
aspirin in this area was performed in patients with PV, a
related MPD [26], which calls into question the direct appli-
cability of the results. In the placebo-controlled European
Collaboration on Low-dose Aspirin in PV (ECLAP) study,
low-dose aspirin (100 mg/day) significantly reduced the risk
of thrombotic complications (non-fatal myocardial infarction
and stroke, death from cardiovascular causes, pulmonary
embolism and major venous thrombosis) [26].
Any long-term therapeutic benefit of aspirin should be
weighed against the potential risk of a major bleeding
episode and gastrointestinal side effects. The relative risk of
major bleeding with aspirin was 1.62 in the ECLAP study,
which was consistent with results in non-PV patients [26].
Table 1 New World Health Organization (WHO) proposed classifi-
cation for essential thrombocythaemia [12]
All the following criteria must be met to diagnose essential
thrombocythaemia:
& Sustained platelet count ≥450×109/l (reduced from ≥600×109/l)
& Bone marrow biopsy specimen showing proliferation mainly of the
megakaryocytic lineage with increased numbers of enlarged,
mature megakaryocytes; no significant increase or left-shift of
neutrophil granulopoiesis or erythropoiesis
& Does not meet the WHO criteria for polycythaemia vera, primary
myelofibrosis, chronic myelogenous leukaemia, myelodysplastic
syndromes or other myeloid neoplasms
& Demonstration of JAK2V617F mutation or other clonal marker, or in
the absence of a clonal marker, no evidence for reactive
thrombocytosis
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Use of aspirin should therefore be avoided in patients with
a history of bleeding or with very high platelet levels
(greater than 1,500×109/l) because of an increased risk of
haemorrhage [27]. Taking the observational and theoretical
evidence into account, aspirin may have a role for the
management of ET, particularly for patients at low risk of
haemorrhagic complications. Noteworthy, however, is that
health economic studies calculating the value of health gain
versus the loss of health due to complications of aspirin
therapy have not been undertaken in ET.
Hydroxycarbamide
Hydroxycarbamide, also known as hydroxyurea, is a non-
specific, cytotoxic, myelosuppressive agent that is used to
treat all MPDs, including ET. Its mechanism of action
involves inhibition of ribonucleotide diphosphate reductase
activity, thus blocking the cell cycle at the G1/S phase and
resulting in cell death [28].
Hydroxycarbamide is an established drug with proven
platelet-reducing efficacy [29–33] and is generally well
tolerated [31, 32]. Results from two randomised controlled
trials confirm that hydroxycarbamide reduces the risk of
thrombotic events in high-risk patients with ET [29, 30].
The Italian study by Cortelazzo et al., in which patients
were randomised to receive hydroxycarbamide (n=56) or
no myelosuppressive therapy (n=58), reported the number
of thrombotic episodes to be significantly lower in the
hydroxycarbamide group than in the control group (3.6%
and 19.0%, respectively; p=0.003) [29]. Noteworthy is that
about 70% of patients in both groups also received anti-
platelet prophylaxis. The United Kingdom Medical Re-
search Council Primary Thrombocythaemia 1 study (MRC
PT-1) compared hydroxycarbamide plus aspirin (n=404)
with anagrelide plus aspirin (n=405) [30]. Rates of major
arterial and venous thrombosis in the hydroxycarbamide
arm (4.2% and 3.5%, respectively) were similar to those
observed in the hydroxycarbamide group of the Cortelazzo
study [29, 30]. The incidence of venous thrombosis was
significantly lower in the anagrelide arm than in the
hydroxycarbamide arm (p=0.006), whereas the incidence
of arterial thrombosis was lower in the hydroxycarbamide
arm (p=0.004). However, the reasons behind these obser-
vations are unclear. Five patients developed myelofibrosis
in the hydroxycarbamide group versus 16 in the anagrelide
group; raising the possibility that hydroxycarbamide may
give better protection against fibrosis. Significantly fewer
haemorrhagic events occurred in the hydroxycarbamide
group than in the anagrelide group, 8 versus 22, respec-
tively (p<0.008). The latter finding may be due to a
synergistic effect between anagrelide and aspirin when
given concomitantly. No significant difference in the
frequency of minor bleedings between treatment groups
was observed [30]. It is noteworthy that a separate
randomised controlled investigation (ANAHYDRET study)
compared hydroxycarbamide and anagrelide in 258 previ-
ously untreated ET patients diagnosed according to the
WHO criteria [34]. The 12-month findings, reported at the
American Society of Hematology congress in 2007,
showed no significant difference in the incidence of
thromboembolic or haemorrhagic events (major events
8 versus 8 and minor events 22 versus 23 for thromboem-
bolic and haemorrhagic events, respectively) between the
hydroxycarbamide and anagrelide arms, suggesting non-
inferiority for anagrelide. However, statistically low numb-
ers preclude a firm conclusion at this timepoint [34].
There is strong evidence to suggest that concomitant or
sequential use of hydroxycarbamide and an alkylating agent
or radioactive phosphorous may increase the risk of
malignant transformation in MPDs, possibly due to the
radiosensitising effect of hydroxycarbamide [35–39]. This
theory is supported by mechanism of action studies, which
show that hydroxycarbamide prevents de novo DNA
synthesis and repair [40]. Interestingly, the bone marrow
of hydroxycarbamide-treated patients shows a dysplastic
appearance, including left-shifting of myelopoiesis, macro-
cytosis of red cells and dysplasia of megakaryocytes, which
is not seen with non-cytostatic drugs [41]. In clinical
studies with more than 96 months median follow-up,
transformation to AML/MDS occurred in 0–22% of
patients with ET/PV treated with hydroxycarbamide as the
sole therapeutic agent [33, 37, 42–46]. The only long-term
study designed to investigate this endpoint shows that
transformation to AML in hydroxycarbamide- or pipobro-
man-treated patients generally occurs after 10 or more
years’ therapy, with the incidence reaching 10–12% after
12 years [45]. In conclusion, the leukaemogenicity of
hydroxycarbamide remains a concern that has not been
diminished by recent data.
The most common side effects of hydroxycarbamide are
granulocytopaenia and anaemia [47], especially after long-
term treatment. Fever of unknown aetiology has also been
observed following initiation of hydroxycarbamide therapy
[48–50]. Cutaneous manifestations are commonly reported
by patients receiving long-term hydroxycarbamide therapy
and are the most frequent reason for treatment cessation
[51–53]. Cutaneous complications include alopecia, xerosis
and scaling, atrophy of the skin and subcutaneous tissues,
skin and nail hyperpigmentation, and cutaneous and
mucocutaneous ulceration [51, 52]. Furthermore, an asso-
ciation between long-term hydroxycarbamide therapy and
multiple skin tumours, including squamous and basal cell
carcinomas, has also been reported [54]. The lower-limb
ulcers caused by hydroxycarbamide are often painful, and
treatment must be withheld to allow the ulcers to heal, but
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this occurs slowly and poorly, occasionally requiring
grafting [55, 56]. In one study, 12 out of 133 patients
(9.0%) receiving hydroxycarbamide developed leg ulcers,
requiring a switch of treatment in ten of these patients [46].
Withdrawal rates of 8–20% due to adverse effects have
been reported in trials [30–32, 46]. According to experts in
the field [57, 58] and evidence-based guidelines [59],
hydroxycarbamide is considered to be the first-choice
cytoreductive therapy in high-risk patients with ET.
However, approximately 15% of patients receiving hydroxy-
carbamide either do not achieve the desired reduction in
platelet counts or develop unacceptable side effects [30–33,
46, 60]. In an attempt to standardise the definition of
resistance and intolerance to hydroxycarbamide, thus when
to stop treatment and switch to an alternative therapy, a
working group consensus definition has recently been
published (Table 2) [61].
Anagrelide
Anagrelide is a cytoreductive agent, with a selective effect
on the megakaryocyte cell lineage [62]. It reduces platelet
production by inhibiting megakaryocyte colony develop-
ment, thus reducing megakaryocyte size, ploidy and
maturation [63]. Several studies have shown that it
effectively lowers platelet counts (overall response rate of
76–94%) and reduces ET-associated complications and
symptoms [63–72]. Anagrelide has been shown in trials to
be as effective as hydroxycarbamide, interferon-α and
alkylating agents in reducing platelet counts, without the
added complication of alkylating or cytotoxic properties
[73], and can be used in patients who are intolerant or
resistant to these cytoreductive agents [64].
Anagrelide is not mutagenic [74], and there is no known
evidence to suggest that it is leukaemogenic [75]. In a long-
term retrospective analysis, anagrelide did not result in
excess conversion to AML, and no ET patient receiving
anagrelide for more than 3 years transformed [64].
Moreover, in a study with a mean follow-up of 12.5 years,
leukaemic transformation did not occur in any of the 39 ET
patients treated with anagrelide [76].
Anagrelide is considered effective for reducing the
incidence of thromboembolic and haemorrhagic complica-
tions. However, this effect has not been investigated in a
placebo-controlled study. Supporting evidence rests mainly
on the comparison with hydroxycarbamide; in particular,
the study by Cortelazzo et al. [29] showing a reduction in
thrombotic events with cytoreductive treatment, and the
results of the PT-1 study [30], demonstrating a similar
incidence of thrombotic events in the anagrelide and
hydroxycarbamide arms to that reported in the Cortelazzo
study. These two studies differed in terms of inclusion
criteria and the use of aspirin; however, the incidence of
thrombosis was the same in both hydroxycarbamide arms,
indicating similarity of the population. The ANAHYDRET
study demonstrated non-inferiority of anagrelide (for
efficacy and ET-related complications) compared with
hydroxycarbamide for the treatment of ET patients at
12 months follow-up (p<0.025) [34]. Furthermore, in a
study of 79 patients with ET, anagrelide significantly
reduced the rate of major thromboembolic complications
compared with the pre-treatment period (p=0.0455) [65].
However, a clear clinical benefit in terms of haemorrhagic
events has not yet been convincingly demonstrated.
The most common side effects of anagrelide include
headache (13–35%) and tachycardia (9–21%), which arise
due to the inhibitory properties of anagrelide on phospho-
diesterase III [65, 66, 69, 70, 73, 77]. The majority of
common side effects are mild or moderate (e.g. WHO grade
1 or 2) and manageable [63–66, 70, 72, 77], with the
frequency and severity dose-dependent [63]. The incidence
of serious side effects is higher in patients aged 60 years or
older than in patients younger than 60 years [64].
Aggravation of cardiac insufficiency is a rare but important
side effect, and special caution is advised in patients with
previous cardiac failure [76, 78]. Anagrelide lowers red
blood cell count by approximately 10% in about 30% of
patients [63, 79], thought to be due to its well-known
vasodilatory properties [63]. Anaemia was detected in
about 50% of patients in a study by Penninga et al. but
was mild and not clinically apparent in most [66]. Low-
grade anaemia was shown to persist during a 2-year follow-
up study, but not to progress.
Appropriate management of side effects may lead to
successful long-term acceptance of medication. In several
studies, the majority of side effects with anagrelide
occurred within 1 month of starting therapy [65, 66, 68,
70, 71], with evidence showing that they subsided during
continued treatment [65–71, 77, 80]. This effect is clearly
Table 2 Consensus definition of clinical resistance or intolerance to
hydroxycarbamide in patients with essential thrombocythaemia (adap-
ted from Barosi et al. [61])
Resistance/intolerance to hydroxycarbamide requires fulfilment of at
least one of the following criteria:
Platelet count
of:
>600,000/μl after 3 months of treatment with at
least 2 g/day hydroxycarbamidea
>400,000/μl and leukocytes <2,500/μl at any dose
of hydroxycarbamide
>400,000/μl and haemoglobin <10 g/dl at any dose
of hydroxycarbamide
Presence of leg ulcers or other unacceptable mucocutaneous
manifestations at any dose of hydroxycarbamide
Fever related to hydroxycarbamide
a 2.5 g/day in patients with a body mass of >80 kg
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illustrated in the study by Storen and Tefferi involving 35
patients younger than 50 years with ET [67]. Comparing
initial (less than 3 months) and longer-term (over 3 months)
anagrelide treatment, the incidence of headache was
reduced from 34.2% to 5.7%, tachycardia from 22.8% to
8.5%, oedema from 14.2% to 5.7% and diarrhoea from
8.5% to 0% [67]. In contrast, a study by Birgegard et al.
showed that the intensity of side effects remained the same
in some patients with long-term treatment [63]. These
findings suggest that it may be beneficial to inform patients
of the possible reduction in side effects with time in order
to improve compliance, especially in the early stages of
treatment. Alternatively, it is feasible that this observed
reduction was due to the withdrawal of patients who cannot
tolerate anagrelide, hence only those patients experiencing
milder side effects were recorded. However, in the study by
Storen and Tefferi, no patients were lost to follow-up;
therefore, it appears that the reduction in side effects might
be related to improved tolerance to treatment with time.
For some ET patients, side effects can be prolonged and
may lead to discontinuation of therapy: 0–50% of patients
were withdrawn from anagrelide treatment in published
studies [63, 64, 68, 69, 80], some because of lack of
response and others because increasing the dose to an
effective level was hindered by side effects.
Interferon-α
The interferon cytokine family demonstrates a wide range
of biological properties, such as immune activation, as well
as anti-proliferative and cell differentiation effects [81].
Based on these properties, interferon-α was first investi-
gated for the treatment of ET in the late 1980s; however, it
has never received an EU licence for a platelet reduction
indication. The mechanism of action of interferon-α is
thought to relate to its anti-proliferative effects on mega-
karyocytes, with reduction in platelet half-life also a
contributing factor [82].
Interferon-α is effective in reducing platelet counts, with a
mean overall response rate of 84.6% [59]. There has been no
randomised comparison of interferon-α with other conven-
tional therapies. Nevertheless, interferon-α is used off-label
as a platelet-reducing alternative agent in MPDs, and is the
only drug suitable for use during pregnancy [59]. It is of note
that interferon-α is not known to be leukaemogenic [75].
Recent results in patients with PV indicate that interfer-
on-α can reduce the percentage of cells expressing the
JAK2 mutant allele (i.e. the JAK2V617F allele burden) [83–
85]. The biological and clinical significance of these results
are unclear, and larger-scale studies are required to confirm
the original findings. To date, no similar results have been
published in patients with ET.
Common side effects of interferon-α include influenza-
like symptoms, nausea, diarrhoea, myalgia, depression and
fatigue [59, 86]. Side effects occur in nearly all patients at
the start of treatment, but they generally abate [59]. For
example, in the study by Yataganas et al. investigating the
use of interferon-α in 18 patients with an MPD (nine with
ET), influenza-like symptoms (e.g. fever higher than 38°C)
lasted a maximum of 4–8 days following treatment
initiation [87]. Despite this abatement, dropout rates
between 15% and 66% have been reported, most commonly
around 25% [88–90].
Given its immunomodulatory properties, interferon-α
may result in symptomatic episodes of autoimmune disease
such as hypothyroidism [91]. There have been reports of
autoimmune thyroiditis [92], arthritis [93], hypertriglycer-
idaemia [94] and ischaemic optic neuropathy [95]. Mood
disorders (depression/mania) are a well-documented side
effect of interferon-α treatment [96–98], and limit the
clinical utility of this agent in the treatment of ET.
The use of pegylated-interferon-α has also been inves-
tigated for the treatment of MPDs. This agent is formulated
from interferon-α by attaching high molecular weight
polymers of ethylene glycol [99]. Such chemical modifica-
tion increases serum half-life and reduces renal excretion,
thus allowing weekly, rather than daily, administration.
Pegylated-interferon-α has been shown to effectively
control platelet count and disease symptoms in patients
with MPDs, including ET [88, 100–102]. However, in two
studies of 38 and 42 patients with an MPD, pegylated-
interferon-α had a similar tolerability profile to conven-
tional interferon-α, with 26% and 50% of patients stopping
therapy due to side effects and the level of toxicity limiting
the duration of therapy [101, 102].
Risk stratification for treatment management
ET is a chronic condition with a prolonged clinical course
that cannot currently be cured. Management, therefore,
relies on the prevention of serious complications, specifi-
cally thrombohaemorrhagic events, through reduction of
the platelet count or by altering platelet function. Manage-
ment is stratified according to risk, categorised as high,
intermediate and low, though the exact definition varies by
investigator and country. In addition to traditional risk
factors, which include previous thrombosis or major
bleeding, age and elevated platelet count, other less
traditional risk factors have also been suggested that may
influence treatment decisions. They include cardiovascular
risk factors and molecular markers (e.g. presence of PRV-1
or JAK2 mutation) [103]. Whether the JAKV2617F muta-
tion should be part of the risk stratification remains an area
of uncertainty. Although evidence on whether the
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JAK2V617F mutation increases the risk of thrombotic
complications is conflicting [104–108], overall it appears
that having the mutation is associated with a slightly higher
risk. Some studies have indicated an association between
leukocytosis and increased risk of thrombosis [10, 109,
110], and one study showed in a time-dependent analysis
that the increased risk was corrected by hydroxycarbamide
treatment [10]. It is possible that the leukocyte count is a
prognostic marker for the activity of the MPD, but it
remains to be proven by further study whether it is an
important marker for treatment efficacy. The evidence for
raised leukocyte levels being a risk factor for survival in ET
is growing, but intervention studies are needed before white
blood cell counts can be a basis for treatment decisions.
Taking into account the available evidence and clinical
experience for various ET treatments, a suggested treatment
algorithm is presented in Fig. 1. The following risk factors
are suggested to define high-risk ET patients: (1) previous
thrombosis or major bleeding; (2) age older than 60 years;
or (3) very high platelet count (>1,500×109/l). Intermedi-
ate-risk ET patients are classified as those without high-risk
criteria, but with hereditary thrombophilia or cardiovascular
risk factors. Low-risk ET patients are without any of these
risk factors.
For high-risk patients, hydroxycarbamide is standard
therapy. However, due to the potential leukemogenicity of
this drug, anagrelide or pegylated-interferon-α are possible
alternative options in ‘young’ patients. This is a difficult
issue and under much debate as currently no consensus has
been reached upon evaluation of the available data. One has
to bear in mind that ET patients have a near-normal life
expectancy, which means that they may be subject to
platelet-reducing therapy for many years. Prospective
studies are needed to decide whether lowering of white
blood cells is an important goal of treatment in ET,
allowing risk/benefit decisions in the choice of treatment
in younger patients. A watch-and-wait approach is recom-
mended for low-risk patients, though low-dose aspirin may
form part of the treatment strategy in this group. Aspirin
should be avoided in patients with platelet counts exceeding
1,000×109/l and the combination of aspirin and anagrelide
should be avoided in patients with previous major bleeding.
The platelet treatment goal is under debate. Previously, a
standard goal was to lower platelet levels below 600×109/l.
However, this threshold appears to be based on the previous
diagnostic platelet level of >600×109/l, rather than evi-
dence from clinical studies. Although there is only sporadic
evidence that a lower treatment goal would provide better
protection against thrombosis, since the new WHO diag-
nostic criteria use a platelet cut-off level of 450×109/l, in
the current discussion a more stringent treatment goal of
400 or 450×109/l in ET patients has been suggested.
Special treatment problems
Patients may be partly unresponsive to any of the three
common drugs for treating ET, or side effects may hinder a
dose increase to an effective level. In these cases, combining
two drugs may be an option. There are no studies exploring
Fig. 1 Proposed treatment algo-
rithm for patients with essential
thrombocythaemia. Reproduced
from Birgegard G. European
Journal of Haematology 2007;
79 (Suppl. 68): 27–31 with
permission of Blackwell Pub-
lishing. CV, cardiovascular; ET,
essential thrombocythaemia;
IFN, interferon-α. The age limit
60 years for the choice of first-
line therapy is the personal
opinion of the author
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such combinations, nor is any combination therapy licensed
for the treatment of ET, but in clinical practice it appears to
be of good use. For example, a patient who develops anaemia
or leukopenia from hydroxycarbamide may also benefit
from receiving low-dose anagrelide, thus allowing the dose
of hydroxycarbamide to be reduced and haemoglobin levels
to be restored. Likewise, a combination of drugs may be
beneficial for patients who cannot tolerate a dose increase
of anagrelide or interferon-α to an effective level.
Patients intolerant to hydroxycarbamide, who either have
cardiac insufficiency or are very old, constitute a special
treatment problem. Anagrelide is not suitable in these
patients, and neither is interferon-α. In this situation,
busulphan may be an option, in spite of its leukaemogenic
properties. A course of busulphan may provide sustained
remission over many months, and the likelihood of devel-
oping leukaemia before death from other causes is low. On
the same grounds, radioactive phosphorous is also an option.
During pregnancy it is not unusual for platelet levels to
fall, but if platelet-reducing therapy is needed, interferon-α
is the only recommended drug [111].
Possible future therapy developments
MPDs are clonal diseases and the ultimate goal must be to
find a cure. However, the treatment of MPDs is a
developing field. The detection of the JAK2V617F mutation
may offer the opportunity for drug development and also
provide a molecular marker for treatment efficacy. In PV,
the reduction in JAK2 allele burden with interferon-α
treatment is of considerable interest [112], and similar
findings have recently been found during hydroxycarba-
mide therapy in PV (personal communication). However,
there have been no reports as to whether this is also true for
ET. It is most likely that the JAK2V617F mutation is not the
only molecular event responsible for development of PV
and, therefore, although JAK2 inhibitors are of great
interest, they are unlikely to provide a cure. This is
especially relevant in ET, where only half of patients carry
the mutation, almost exclusively in heterozygous form [3].
However, if JAK2 inhibitors prove to be effective for
reducing platelet numbers, the discussion will concern
whether the expected high cost of such drugs is warranted
for symptomatic treatment. One can, therefore, expect the
current platelet-reducing agents to maintain their place in
the therapy of ET for the foreseeable future.
Conclusions
The objective of ET treatment is to reduce the risk of
thromboembolic and haemorrhagic complications associat-
ed with the disorder. Treatment is given according to risk
stratification: platelet reduction should be given in high-risk
patients and selected intermediate-risk patients, whereas no
treatment or aspirin should be used in low-risk patients.
Hydroxycarbamide is currently first-line therapy in patients
older than 60 years of age, whereas non-mutagenic drugs
like anagrelide and interferon-α might be considered in
younger patients and those clinically intolerant or resistant
to hydroxycarbamide.
Acknowledgements Medical writing assistance was provided by
Fishawack Communications and financial support was provided by
Shire.
Conflicts of interest Prof. Dr Birgegård has received unrestricted
research support from Schering-Plough and Shire, as well as fees for
speaking assignments from Shire.
Open Access This article is distributed under the terms of the Creative
Commons Attribution Noncommercial License which permits any
noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
References
1. Briere JB (2007) Essential thrombocythemia. Orphanet J Rare
Dis 2:3 doi:10.1186/1750-1172-2-3
2. Jensen MK, de Nully Brown P, Nielsen OJ, Hasselbalch HC
(2000) Incidence, clinical features and outcome of essential
thrombocythaemia in a well defined geographical area. Eur J
Haematol 65:132–139 doi:10.1034/j.1600-0609.2000.90236.x
3. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden
JT et al (2005) Definition of subtypes of essential thrombocy-
thaemia and relation to polycythaemia vera based on JAK2
V617F mutation status: a prospective study. Lancet 366:1945–
1953 doi:10.1016/S0140-6736(05)67785-9
4. Sanchez S, Ewton A (2006) Essential thrombocythemia: a
review of diagnostic and pathologic features. Arch Pathol Lab
Med 130:1144–1150
5. Penninga EI, Bjerrum OW (2006) Polycythaemia vera and
essential thrombocythaemia: current treatment strategies. Drugs
66:2173–2187 doi:10.2165/00003495-200666170-00003
6. Harrison CN, Gale RE, Machin SJ, Linch DC (1999) A large
proportion of patients with a diagnosis of essential thrombocy-
themia do not have a clonal disorder and may be at lower risk of
thrombotic complications. Blood 93:417–424
7. Griesshammer M, Klippel S, Strunck E, Temerinac S, Mohr U,
Heimpel H et al (2004) PRV-1 mRNA expression discriminates
two types of essential thrombocythemia. Ann Hematol 83:364–
370 doi:10.1007/s00277-004-0864-9
8. Teofili L, Pierconti F, Di Febo A, Maggiano N, Vianelli N,
Ascani S et al (2002) The expression pattern of c-mpl in mega-
karyocytes correlates with thrombotic risk in essential thrombocy-
themia. Blood 100:714–717 doi:10.1182/blood.V100.2.714
9. Kralovics R, Buser AS, Teo SS, Coers J, Tichelli A, van der
Maas AP et al (2003) Comparison of molecular markers in a
cohort of patients with chronic myeloproliferative disorders.
Blood 102:1869–1871 doi:10.1182/blood-2003-03-0744
10. Carobbio A, Finazzi G, Guerini V, Spinelli O, Delaini F,
Marchioli R et al (2007) Leukocytosis is a risk factor for
Ann Hematol (2009) 88:1–10 7
thrombosis in essential thrombocythemia: interaction with
treatment, standard risk factors, and JAK2 mutation status.
Blood 109:2310–2313 doi:10.1182/blood-2006-09-046342
11. Harrison CN (2005) Essential thrombocythaemia: challenges and
evidence-based management. Br J Haematol 130:153–165
doi:10.1111/j.1365-2141.2005.05543.x
12. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson
CA et al (2007) Proposals and rationale for revision of the World
Health Organization diagnostic criteria for polycythemia vera,
essential thrombocythemia, and primary myelofibrosis: recom-
mendations from an ad hoc international expert panel. Blood
110:1092–1097 doi:10.1182/blood-2007-04-083501
13. Thiele J, Kvasnicka HM (2007) Myelofibrosis—what’s in a
name? Consensus on definition and EUMNET grading. Patho-
biology 74:89–96 doi:10.1159/000101708
14. Kvasnicka HM, Thiele J (2006) The impact of clinicopathological
studies on staging and survival in essential thrombocythemia,
chronic idiopathic myelofibrosis, and polycythemia rubra vera.
Semin Thromb Hemost 32:362–371 doi:10.1055/s-2006-942757
15. Thiele J, Kvasnicka HM, Schmitt-Graeff A, Zankovich R, Diehl
V (2002) Follow-up examinations including sequential bone
marrow biopsies in essential thrombocythemia (ET): a retrospec-
tive clinicopathological study of 120 patients. Am J Hematol
70:283–291 doi:10.1002/ajh.10116
16. Buhr T, Georgii A, Choritz H (1993) Myelofibrosis in chronic
myeloproliferative disorders. Incidence among subtypes accord-
ing to the Hannover Classification. Pathol Res Pract 189:121–
132
17. Kreft A, Buche G, Ghalibafian M, Buhr T, Fischer T, Kirkpatrick
CJ (2005) The incidence of myelofibrosis in essential thrombo-
cythaemia, polycythaemia vera and chronic idiopathic myelofi-
brosis: a retrospective evaluation of sequential bone marrow
biopsies. Acta Haematol 113:137–143 doi:10.1159/000083452
18. Wilkins BS, Erber WN, Bareford D, Buck G, Wheatley K, East
CL et al (2008) Bone marrow pathology in essential thrombo-
cythemia: interobserver reliability and utility for identifying
disease subtypes. Blood 111:60–70 doi:10.1182/blood-2007-05-
091850
19. Colwell JA (2006) Aspirin for the primary prevention of
cardiovascular events. Timely Top Med Cardiovasc Dis 10:E25
20. Landolfi R, Ciabattoni G, Patrignani P, Castellana MA, Pogliani
E, Bizzi B et al (1992) Increased thromboxane biosynthesis in
patients with polycythemia vera: evidence for aspirin-suppress-
ible platelet activation in vivo. Blood 80:1965–1971
21. Rocca B, Ciabattoni G, Tartaglione R, Cortelazzo S, Barbui T,
Patrono C et al (1995) Increased thromboxane biosynthesis in
essential thrombocythemia. Thromb Haemost 74:1225–1230
22. Randi ML, Rossi C, Fabris F, Menapace L, Girolami A (1999)
Aspirin seems as effective as myelosuppressive agents in the
prevention of rethrombosis in essential thrombocythemia. Clin
Appl Thromb Hemost 5:131–135 doi:10.1177/107602969
900500210
23. van Genderen PJ, Mulder PG, Waleboer M, van de Moesdijk D,
Michiels JJ (1997) Prevention and treatment of thrombotic
complications in essential thrombocythaemia: efficacy and safety
of aspirin. Br J Haematol 97:179–184 doi:10.1046/j.1365-
2141.1997.d01-2127.x
24. Michiels JJ, Koudstaal PJ, Mulder AH, van Vliet HH (1993)
Transient neurologic and ocular manifestations in primary
thrombocythemia. Neurology 43:1107–1110
25. van Genderen PJ, Michiels JJ, van Strik R, Lindemans J, van
Vliet HH (1995) Platelet consumption in thrombocythemia
complicated by erythromelalgia: reversal by aspirin. Thromb
Haemost 73:210–214
26. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G,
Patrono C et al (2004) Efficacy and safety of low-dose aspirin in
polycythemia vera. N Engl J Med 350:114–124 doi:10.1056/
NEJMoa035572
27. Griesshammer M, Bangerter M, van Vliet HH, Michiels JJ
(1997) Aspirin in essential thrombocythemia: status quo and quo
vadis. Semin Thromb Hemost 23:371–377
28. Navarra P, Preziosi P (1999) Hydroxyurea: new insights on an
old drug. Crit Rev Oncol Hematol 29:249–255 doi:10.1016/
S1040-8428(98)00032-8
29. Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M,
Rodeghiero F et al (1995) Hydroxyurea for patients with
essential thrombocythemia and a high risk of thrombosis. N Engl
J Med 332:1132–1136 doi:10.1056/NEJM199504273321704
30. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL,
Bareford D et al (2005) Hydroxyurea compared with anagrelide
in high-risk essential thrombocythemia. N Engl J Med 353:33–
45 doi:10.1056/NEJMoa043800
31. Lofvenberg E, Wahlin A (1988) Management of polycythaemia
vera, essential thrombocythaemia and myelofibrosis with hy-
droxyurea. Eur J Haematol 41:375–381
32. Randi ML, Ruzzon E, Luzzatto G, Tezza F, Girolami A, Fabris F
(2005) Safety profile of hydroxyurea in the treatment of patients
with Philadelphia-negative chronic myeloproliferative disorders.
Haematologica 90:261–262
33. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T (2003) Efficacy
and safety of long-term use of hydroxyurea in young patients
with essential thrombocythemia and a high risk of thrombosis.
Blood 101:3749 doi:10.1182/blood-2003-01-0135
34. Gisslinger H, Kralovics R, Gotic M, Holowiecki J, Penka M,
Widmann R et al (2007) Non-inferiority of anagrelide compared
to hydroxyurea in newly diagnosed patients with essential
thrombocythaemia: the ANAHYDRET study. In: 49th Annual
Society of Hematology Annual Meeting, Atlanta, USA, 8–11
December
35. Najean Y, Rain JD, The French Polycythemia Study Group
(1997) Treatment of polycythemia vera: use of 32P alone or in
combination with maintenance therapy using hydroxyurea in 461
patients greater than 65 years of age. Blood 89:2319–2327
36. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T (2000) Second
malignancies in patients with essential thrombocythaemia treated
with busulphan and hydroxyurea: long-term follow-up of a
randomized clinical trial. Br J Haematol 110:577–583 doi:
10.1046/j.1365-2141.2000.02188.x
37. Sterkers Y, Preudhomme C, Lai JL, Demory JL, Caulier MT,
Wattel E et al (1998) Acute myeloid leukemia and myelodys-
plastic syndromes following essential thrombocythemia treated
with hydroxyurea: high proportion of cases with 17p deletion.
Blood 91:616–622
38. Randi ML, Fabris F, Girolami A (2002) Second malignancies in
patients with essential thrombocythaemia. Br J Haematol
116:923–924 doi:10.1111/j.1365-2141.2002.3346_1.x
39. Murphy S, Peterson P, Iland H, Laszlo J (1997) Experience of
the Polycythemia Vera Study Group with essential thrombocy-
themia: a final report on diagnostic criteria, survival, and
leukemic transition by treatment. Semin Hematol 34:29–39
40. Gwilt PR, Tracewell WG (1998) Pharmacokinetics and pharma-
codynamics of hydroxyurea. Clin Pharmacokinet 34:347–358
doi:10.2165/00003088-199834050-00002
41. Thiele J, Kvasnicka HM, Ollig S, Schmitt-Graff A (2005)
Anagrelide does not exert a myelodysplastic effect on mega-
karyopoiesis: a comparative immunohistochemical and mor-
phometric study with hydroxyurea. Histol Histopathol 20:
1071–1076
42. Bernasconi P, Boni M, Cavigliano PM, Calatroni S, Brusamolino
E, Passamonti F et al (2002) Acute myeloid leukemia (AML)
having evolved from essential thrombocythemia (ET): distinctive
chromosome abnormalities in patients treated with pipobroman
8 Ann Hematol (2009) 88:1–10
or hydroxyurea. Leukemia 16:2078–2083 doi:10.1038/sj.leu.
2402638
43. Chim CS, Kwong YL, Lie AK, Ma SK, Chan CC, Wong LG et
al (2005) Long-term outcome of 231 patients with essential
thrombocythemia: prognostic factors for thrombosis, bleeding,
myelofibrosis, and leukemia. Arch Intern Med 165:2651–2658
doi:10.1001/archinte.165.22.2651
44. Fruchtman SM, Mack K, Kaplan ME, Peterson P, Berk PD,
Wasserman LR (1997) From efficacy to safety: a Polycythemia
Vera Study group report on hydroxyurea in patients with
polycythemia vera. Semin Hematol 34:17–23
45. Kiladjian JJ, Rain JD, Bernard JF, Briere J, Chomienne C,
Fenaux P (2006) Long-term incidence of hematological evolu-
tion in three French prospective studies of hydroxyurea and
pipobroman in polycythemia vera and essential thrombocythe-
mia. Semin Thromb Hemost 32:417–421 doi:10.1055/s-2006-
942762
46. Najean Y, Rain JD (1997) Treatment of polycythemia vera: the
use of hydroxyurea and pipobroman in 292 patients under the
age of 65 years. Blood 90:3370–3377
47. Stevens MR (1999) Hydroxyurea: an overview. J Biol Regul
Homeost Agents 13:172–175
48. Lossos IS, Matzner Y (1995) Hydroxyurea-induced fever: case
report and review of the literature. Ann Pharmacother 29:132–
133
49. Braester A, Quitt M (2000) Hydroxyurea as a cause of drug
fever. Acta Haematol 104:50–51 doi:10.1159/000041071
50. Lannemyr O, Kutti J (1999) Hydroxyurea as a cause of drug fever
in essential thrombocythaemia. Eur J Haematol 62:354–355
51. Kennedy BJ, Smith LR, Goltz RW (1975) Skin changes
secondary to hydroxyurea therapy. Arch Dermatol 111:183–187
doi:10.1001/archderm.111.2.183
52. Dumont-Wallon G, Milpied-Homsi B, Morineau N (2006) Effets
secondaires cutanéomuqueux de l’hydroxyurée: étude prospec-
tive sur 27 patients. Hematologie 12:262–266
53. Zaccaria E, Cozzani E, Parodi A (2006) Secondary cutaneous
effects of hydroxyurea: possible pathogenetic mechanisms. J
Dermatolog Treat 17:176–178 doi:10.1080/09546630600780494
54. Best PJ, Petitt RM (1998) Multiple skin cancers associated with
hydroxyurea therapy. Mayo Clin Proc 73:961–963
55. Ravandi-Kashani F, Cortes J, Cohen P, Talpaz M, O’Brien S,
Markowitz A et al (1999) Cutaneous ulcers associated with
hydroxyurea therapy in myeloproliferative disorders. Leuk
Lymphoma 35:109–118 doi:10.3109/10428199909145710
56. Gilbert HS (2003) Modern treatment strategies in polycythemia
vera. Semin Hematol 40:26–29
57. Barbui T, Finazzi G (2005) When and how to treat essential
thrombocythemia. N Engl J Med 353:85–86 doi:10.1056/
NEJMe058093
58. Dingli D, Tefferi A (2005) A critical review of anagrelide
therapy in essential thrombocythemia and related disorders. Leuk
Lymphoma 46:641–650 doi:10.1080/10428190400029817
59. Barbui T, Barosi G, Grossi A, Gugliotta L, Liberato LN,
Marchetti M et al (2004) Practice guidelines for the therapy of
essential thrombocythemia. A statement from the Italian Society
of Hematology, the Italian Society of Experimental Hematology
and the Italian Group for Bone Marrow Transplantation.
Haematologica 89:215–232
60. RandiML, Ruzzon E, Tezza F, Luzzatto G, Fabris F (2005) Toxicity
and side effects of hydroxyurea used for primary thrombocythemia.
Platelets 16:181–184 doi:10.1080/09537100400020179
61. Barosi G, Besses C, Birgegard G, Briere J, Cervantes F, Finazzi
G et al (2007) A unified definition of clinical resistance/
intolerance to hydroxyurea in essential thrombocythemia: results
of a consensus process by an international working group.
Leukemia 21:277–280 doi:10.1038/sj.leu.2404473
62. Hong Y, Wang G, Del Arroyo AG, Hernandez J, Skene C,
Erusalimsky JD (2006) Comparison between anagrelide and
hydroxycarbamide in their activities against haematopoietic
progenitor cell growth and differentiation: selectivity of anagre-
lide for the megakaryocytic lineage. Leukemia 20:1117–1122
doi:10.1038/sj.leu.2404180
63. Birgegard G, Bjorkholm M, Kutti J, Larfars G, Lofvenberg E,
Markevarn B et al (2004) Adverse effects and benefits of two
years of anagrelide treatment for thrombocythemia in chronic
myeloproliferative disorders. Haematologica 89:520–527
64. Fruchtman SM, Petitt RM, Gilbert HS, Fiddler G, Lyne A (2005)
Anagrelide: analysis of long-term efficacy, safety and leukemo-
genic potential in myeloproliferative disorders. Leuk Res
29:481–491 doi:10.1016/j.leukres.2004.10.002
65. Steurer M, Gastl G, Jedrzejczak WW, Pytlik R, Lin W, Schlogl E
et al (2004) Anagrelide for thrombocytosis in myeloproliferative
disorders: a prospective study to assess efficacy and adverse
event profile. Cancer 101:2239–2246 doi:10.1002/cncr.20646
66. Penninga E, Jensen BA, Hansen PB, Clausen NT, Mourits-
Andersen T, Nielsen OJ et al (2004) Anagrelide treatment in 52
patients with chronic myeloproliferative diseases. Clin Lab
Haematol 26:335–340 doi:10.1111/j.1365-2257.2004.00637.x
67. Storen EC, Tefferi A (2001) Long-term use of anagrelide in
young patients with essential thrombocythemia. Blood 97:863–
866 doi:10.1182/blood.V97.4.863
68. Laguna MS, Kornblihtt LI, Marta RF, Michiels JJ, Molinas FC
(2000) Effectiveness of anagrelide in the treatment of symptom-
atic patients with essential thrombocythemia. Clin Appl Thromb
Hemost 6:157–161 doi:10.1177/107602960000600307
69. Mills AK, Taylor KM, Wright SJ, Bunce I, Eliadis P, Brigden
MC et al (1999) Efficacy, safety and tolerability of anagrelide in
the treatment of essential thrombocythaemia. Aust N Z J Med
29:29–35
70. Petrides PE, Beykirch MK, Trapp OM (1998) Anagrelide, a
novel platelet lowering option in essential thrombocythaemia:
treatment experience in 48 patients in Germany. Eur J Haematol
61:71–76
71. Anagrelide Study Group (1992) Anagrelide, a therapy for
thrombocythemic states: experience in 577 patients. Am J Med
92:69–76 doi:10.1016/0002-9343(92)90017-6
72. Petitt RM, Silverstein MN, Petrone ME (1997) Anagrelide for
control of thrombocythemia in polycythemia and other myelo-
proliferative disorders. Semin Hematol 34:51–54
73. Mazzucconi MG, De Sanctis V, Chistolini A, Dragoni F,
Mandelli F (1992) Therapy with anagrelide in patients affected
by essential thrombocythemia: preliminary results. Haematolog-
ica 77:315–317
74. Petrides PE (2004) Anagrelide: a decade of clinical experience
with its use for the treatment of primary thrombocythaemia.
Expert Opin Pharmacother 5:1781–1798 doi:10.1517/14656566.
5.8.1781
75. Barbui T (2004) The leukemia controversy in myeloproliferative
disorders: is it a natural progression of disease, a secondary
sequela of therapy, or a combination of both. Semin Hematol
41:15–17 doi:10.1053/j.seminhematol.2004.02.006
76. Mazzucconi MG, Redi R, Bernasconi S, Bizzoni L, Dragoni F,
Latagliata R et al (2004) A long-term study of young patients
with essential thrombocythemia treated with anagrelide. Haema-
tologica 89:1306–1313
77. Zomas A, Marinakis T, Grigoraki V, Gortzolidis G, Arseni P,
Skandali A et al (2002) The use anagrelide for control of
thrombocytosis in Greek patients with myeloproliferative dis-
orders. Haem 5:320–325
78. Birgegard G (2006) Anagrelide treatment in myeloproliferative
disorders. Semin Thromb Hemost 32:260–266 doi:10.1055/s-
2006-939437
Ann Hematol (2009) 88:1–10 9
79. Gilbert HS (2001) Diagnosis and treatment of thrombocythemia
in myeloproliferative disorders. Oncology 15:989–996 Williston
Park
80. Mazur G, Wrobel T, Podolak-Dawidziak M, Kuliszkiewicz-
Janus M, Potoczek S, Nosol J et al (2004) Anagrelide in the
treatment of thrombocythemia essential (ET). Pol Arch Med
Wewn 112:1445–1450
81. Tefferi A, Silverstein MN (1998) Treatment of polycythaemia
vera and essential thrombocythaemia. Baillieres Clin Haematol
11:769–785 doi:10.1016/S0950-3536(98)80038-3
82. Wadenvik H, Kutti J, Ridell B, Revesz P, Jacobsson S,
Magnusson B et al (1991) The effect of alpha-interferon on
bone marrow megakaryocytes and platelet production rate in
essential thrombocythemia. Blood 77:2103–2108
83. Kiladjian JJ, Cassinat B, Turlure P, Cambier N, Roussel M,
Bellucci S et al (2006) High molecular response rate of
polycythemia vera patients treated with pegylated interferon
alpha-2a. Blood 108:2037–2040 doi:10.1182/blood-2006-03-
009860
84. Samuelsson J, Mutschler M, Birgegard G, Gram-Hansen P,
Bjorkholm M, Pahl HL (2006) Limited effects on JAK2
mutational status after pegylated interferon alpha-2b therapy in
polycythemia vera and essential thrombocythemia. Haematolog-
ica 91:1281–1282
85. Jones AV, Silver RT, Waghorn K, Curtis C, Kreil S, Zoi K et al
(2006) Minimal molecular response in polycythemia vera
patients treated with imatinib or interferon alpha. Blood
107:3339–3341 doi:10.1182/blood-2005-09–3917
86. Seewann HL (1993) Interferon therapy in essential thrombocy-
themia. Wien Med Wochenschr 143:420–424
87. Yataganas X, Meletis J, Plata E, Viniou N, Deligiannis F,
Tsekoura C et al (1991) alpha Interferon treatment of essential
thrombocythaemia and other myeloproliferative disorders with
excessive thrombocytosis. Eur J Cancer 27(Suppl 4):S69–S71
88. Samuelsson J, Hasselbalch H, Bruserud O, Temerinac S,
Brandberg Y, Merup M et al (2006) A phase II trial of pegylated
interferon alpha-2b therapy for polycythemia vera and essential
thrombocythemia: feasibility, clinical and biologic effects, and
impact on quality of life. Cancer 106:2397–2405 doi:10.1002/
cncr.21900
89. Lengfelder E, Griesshammer M, Hehlmann R (1996) Interferon-
alpha in the treatment of essential thrombocythemia. Leuk
Lymphoma 22(Suppl 1):135–142 doi:10.3109/10428199609074371
90. Lengfelder E, Berger U, Hehlmann R (2000) Interferon alpha in
the treatment of polycythemia vera. Ann Hematol 79:103–109
doi:10.1007/s002770050563
91. Gilbert HS (2002) Other secondary sequelae of treatments for
myeloproliferative disorders. Semin Oncol 29:22–27
92. Gisslinger H, Chott A, Scheithauer W, Gilly B, Linkesch W,
Ludwig H (1991) Interferon in essential thrombocythaemia. Br J
Haematol 79(Suppl 1):42–47 doi:10.1111/j.1365-2141.1991.
tb08118.x
93. Çabuk M, Pirildar T, Ceylan C, Koral L, Kirmaz C, Kiliccioglu
B et al (2003) Arthritis induced by interferon-alpha therapy in a
patient with essential thrombocythemia. Leuk Lymphoma
44:377–378 doi:10.1080/1042819021000029948
94. De Salvo L, Plumacher Z, Gomez O, Weir-Medina J, Paz L,
Salas D (1996) Hypertriglyceridemia following treatment with
interferon alpha in essential thrombocythemia. Invest Clin
37:177–181
95. Vardizer Y, Linhart Y, Loewenstein A, Garzozi H, Mazawi N,
Kesler A (2003) Interferon-alpha-associated bilateral simulta-
neous ischemic optic neuropathy. J Neuroophthalmol 23:256–
259 doi:10.1097/00041327-200312000-00003
96. Merup M, Aberg W, Lofvenberg E, Svensson E, Engman K,
Paul C et al (2002) Symptoms, symptom distress and health-
related quality of life in patients with polycythaemia vera or
essential thrombocythaemia during treatment with interferon-
alpha. Acta Oncol 41:50–55 doi:10.1080/028418602317314064
97. Malek-Ahmadi P, Hilsabeck RC (2007) Neuropsychiatric com-
plications of interferons: classification, neurochemical bases, and
management. Ann Clin Psychiatry 19:113–123 doi:10.1080/
10401230701333038
98. Malek-Ahmadi P (2001) Mood disorders associated with
interferon treatment: theoretical and practical considerations.
Ann Pharmacother 35:489–495 doi:10.1345/aph.10172
99. Quintas-Cardama A, Kantarjian HM, Giles F, Verstovsek S
(2006) Pegylated interferon therapy for patients with Philadel-
phia chromosome-negative myeloproliferative disorders. Semin
Thromb Hemost 32:409–416 doi:10.1055/s-2006-942761
100. Alvarado Y, Cortes J, Verstovsek S, Thomas D, Faderl S, Estrov
Z et al (2003) Pilot study of pegylated interferon-alpha 2b in
patients with essential thrombocythemia. Cancer Chemother
Pharmacol 51:81–86 doi:10.1007/s00280-002-0533-4
101. Langer C, Lengfelder E, Thiele J, Kvasnicka HM, Pahl HL,
Beneke H et al (2005) Pegylated interferon for the treatment of
high risk essential thrombocythemia: results of a phase II study.
Haematologica 90:1333–1338
102. Jabbour E, Kantarjian H, Cortes J, Thomas D, Garcia-Manero G,
Ferrajoli A et al (2007) PEG-IFN-alpha-2b therapy in BCR-
ABL-negative myeloproliferative disorders: final result of a
Phase 2 study. Cancer 110:2012–2018 doi:10.1002/cncr.23018
103. Griesshammer M (2006) Risk factors for thrombosis and
bleeding and their influence on therapeutic decisions in patients
with essential thrombocythemia. Semin Thromb Hemost
32:372–380 doi:10.1055/s-2006-942758
104. Wolanskyj AP, Lasho TL, Schwager SM, McClure RF, Wadleigh
M, Lee SJ et al (2005) JAK2 mutation in essential thrombocy-
thaemia: clinical associations and long-term prognostic rele-
vance. Br J Haematol 131:208–213 doi:10.1111/j.1365-2141.
2005.05764.x
105. Tefferi A (2006) Essential thrombocythemia: scientific advances
and current practice. Curr Opin Hematol 13:93–98
106. Kittur J, Knudson RA, Lasho TL, Finke CM, Gangat N,
Wolanskyj AP et al (2007) Clinical correlates of JAK2V617F
allele burden in essential thrombocythemia. Cancer 109:2279–
2284 doi:10.1002/cncr.22663
107. Finazzi G, Rambaldi A, Guerini V, Carobbo A, Barbui T (2007)
Risk of thrombosis in patients with essential thrombocythemia
and polycythemia vera according to JAK2 V617F mutation
status. Haematologica 92:135–136 doi:10.3324/haematol.10634
108. Hsiao HH, Yang MY, Liu YC, Lee CP, Yang WC, Liu TC et al
(2007) The association of JAK2(V617F) mutation and leukocy-
tosis with thrombotic events in essential thrombocythemia. Exp
Hematol 35:1704–1707 doi:10.1016/j.exphem.2007.08.011
109. Tefferi A, Elliott M (2007) Thrombosis in myeloproliferative
disorders: prevalence, prognostic factors, and the role of
leukocytes and JAK2V617F. Semin Thromb Hemost 33:313–
320 doi:10.1055/s-2007-976165
110. Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi
A (2006) Essential thrombocythemia beyond the first decade: life
expectancy, long-term complication rates, and prognostic factors.
Mayo Clin Proc 81:159–166
111. Griesshammer M, Struve S, Harrison CM (2006) Essential
thrombocythemia/polycythemia vera and pregnancy: the need
for an observational study in Europe. Semin Thromb Hemost
32:422–429 doi:10.1055/s-2006-942763
112. Kiladjian JJ, Casadevall N, Vainchenker W, Fenaux P (2007)
The first international meeting on V617F JAK2 mutation and
its relevance in Philadelphia-negative myeloproliferative disor-
ders. Pathol Biol (Paris) 55:85–87 doi:10.1016/j.patbio.2006.
06.004
10 Ann Hematol (2009) 88:1–10
